智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)收到国家药品监督管理局关于同意注射用HLX316(即靶向B7-H3的唾液酸酶Fc融合蛋白，简称“HLX316”)用于晚期/转移性实体瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后在中国境内1开展该药品的相关临床研究。
HLX316系集团利用靶向B7-H3的仅含重链的抗体可变区(VHH)与许可引进的唾液酸酶双功能融合蛋白融合开发的唾液酸酶Fc融合蛋白，为一种新型、首创、靶向B7-H3的唾液酸酶异源二聚体，拟用于晚期/转移性实体瘤治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.